1. Home
  2. QRHC vs BTAI Comparison

QRHC vs BTAI Comparison

Compare QRHC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quest Resource Holding Corporation

QRHC

Quest Resource Holding Corporation

N/A

Current Price

$1.12

Market Cap

24.7M

Sector

Utilities

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QRHC
BTAI
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.7M
35.6M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
QRHC
BTAI
Price
$1.12
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
90.2K
891.8K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
$138,346,327.00
N/A
Revenue This Year
$3.67
$131.31
Revenue Next Year
N/A
$1,668.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$1.01
52 Week High
$2.65
$8.08

Technical Indicators

Market Signals
Indicator
QRHC
BTAI
Relative Strength Index (RSI) 40.81 31.11
Support Level $1.11 N/A
Resistance Level $1.33 $1.77
Average True Range (ATR) 0.07 0.11
MACD 0.03 -0.02
Stochastic Oscillator 22.50 9.37

Price Performance

Historical Comparison
QRHC
BTAI

About QRHC Quest Resource Holding Corporation

Quest Resource Holding Corp is a national provider of waste and recycling services to customers from across multiple industry sectors that are typically larger, multi-location businesses. The company creates customer-specific programs and perform the related services for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's services focus on the waste streams and recyclables from box, grocers, and other specialty retailers; automotive after-market operations such as automotive maintenance, quick lube, dealerships, and collision repair; transportation, logistics, and fleet operators; manufacturing and industrial facilities; multi-family and commercial properties; restaurant chains and food operations, etc.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: